TBPH (STOCKS)
Theravance Biopharma, Inc.
$16.340000
-0.300000 (-1.80%)
Prev close: $16.640000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Rick E. Winningham
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $842.12M
- Employees
- 97
- P/E (TTM)
- 7.55
- P/B (TTM)
- 2.95
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
4
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.03 | $-0.15 | +0.1162 | +79.48% |
|
Dec 2025 (Q4)
|
$0.21 | $1.24 | -1.0338 | -83.12% |
|
Sep 2025 (Q3)
|
$0.07 | $-0.13 | +0.2009 | +153.48% |
|
Jun 2025 (Q2)
|
$-0.54 | $0.69 | -1.2265 | -178.66% |
Financial Statements
| Revenues | $109.78M |
| Benefits Costs and Expenses | $24.17M |
| Costs And Expenses | $105.41M |
| Operating Expenses | $108.43M |
| Selling, General, and Administrative Expenses | $73.00M |
| Research and Development | $31.79M |
| Operating Income/Loss | $1.35M |
| Income/Loss From Continuing Operations After Tax | $114.54M |
| Income/Loss From Continuing Operations Before Tax | $62.73M |
| Income Tax Expense/Benefit | $22.37M |
| Net Income/Loss | $114.54M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $114.54M |
| Net Income/Loss Available To Common Stockholders, Basic | $114.54M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $2.26 |
| Diluted Earnings Per Share | $2.20 |
| Basic Average Shares | 51,890,000 |
| Diluted Average Shares | 53,080,000 |
| Assets | $472.31M |
| Current Assets | $417.63M |
| Noncurrent Assets | $54.68M |
| Fixed Assets | $5.54M |
| Other Non-current Assets | $49.14M |
| Liabilities | $181.72M |
| Current Liabilities | $31.78M |
| Accounts Payable | $1.10M |
| Wages | $8.73M |
| Other Current Liabilities | $21.95M |
| Noncurrent Liabilities | $149.94M |
| Equity | $290.59M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $290.59M |
| Liabilities And Equity | $472.31M |
| Net Cash Flow From Operating Activities | $268.78M |
| Net Cash Flow From Operating Activities, Continuing | $268.78M |
| Net Cash Flow From Investing Activities | -$83.32M |
| Net Cash Flow From Investing Activities, Continuing | -$83.32M |
| Net Cash Flow From Financing Activities | -$7.97M |
| Net Cash Flow From Financing Activities, Continuing | -$7.97M |
| Net Cash Flow | $177.49M |
| Net Cash Flow, Continuing | $177.49M |
| Comprehensive Income/Loss | $114.42M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $114.46M |
| Other Comprehensive Income/Loss | -$123.00K |